Ligand Pharmaceuticals Incorporated
LGND · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $268M | $167M | +60.4% |
| Operating income | $41.0M | −$22.6M | |
| Net income | $124M | −$4.03M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 30, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $78.7M | $116M | −31.9% |
| Operating income | −$15.8M | $55.4M | |
| Net income | −$28.5M | $117M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Ligand's revenue in FY2025?
- $268M in FY2025 (Fiscal year ended Dec 31, 2025), +60.4% vs $167M a year earlier, per its 10-K filed Feb 2026.
- Was Ligand profitable in FY2025?
- Yes: net income was $124M and operating income $41.0M in FY2025.
- What was Ligand's revenue in Q3 2026?
- $78.7M (−31.9% vs a year earlier), per its Form 10-Q filed Oct 30, 2026.